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Abstract: Breast cancer remains a major health problem worldwide. While chemotherapy 
represents an important therapeutic modality against breast cancer, limitations in the 
clinical use of chemotherapy remain formidable because of chemoresistance. The 
HER2/PI-3K/Akt pathway has been demonstrated to play a causal role in conferring a 
broad chemoresistance in breast cancer cells and thus justified to be a target for enhancing 
the effects of anti-breast cancer chemotherapies, such as adriamycin (ADR). Agents that 
can either enhance the effects of chemotherapeutics or overcome chemoresistance are 
urgently needed for the treatment of breast cancer. In this context, SZ-685C, an agent that 
has been previously shown, as such, to suppress Akt signaling, is expected to increase the 
efficacy of chemotherapy. Our current study investigated whether SZ-685C can override 
chemoresistance through inhibiting Akt signaling in human breast cancer cells.   
ADR-resistant cells derived from human breast cancer cell lines MCF-7, MCF-7/ADR and 
MCF-7/Akt, were used as models to test the effects of SZ-685C. We found that SZ-685C 
suppressed the Akt pathway and induced apoptosis in MCF-7/ADR and MCF-7/Akt cells 
that are resistant to ADR treatment, leading to antitumor effects both in vitro and in vivo. 
Our data suggest that use of SZ-685C might represent a potentially promising approach to 
the treatment of ADR-resistant breast cancer. 
Keywords: SZ-685C; breast cancer; chemoresistance; Akt 
 
1. Introduction 
Chemotherapy remains an important and irreplaceable modality of cancer treatment that utilizes 
chemical drugs to kill, or inhibit, the growth of cancer cells. To date, hundreds of compounds have 
been used in cancer chemotherapy [1]. Employment of chemotherapy in patients with cancer, however, 
often fails to achieve clinical benefit due to severe adverse effects. Furthermore, development of 
resistant to chemotherapeutic drugs, particularly through multidrug resistance (MDR), represents a 
major impediment to successful chemotherapy [2]. Tumor cells are found to adopt multiple 
mechanisms to resist drugs, including decreased uptake of drugs and/or enhanced efflux of drugs, 
altered metabolism of drugs, alterations in drug targets, activation of the detoxification system, 
enhanced DNA repair ability and inhibition of apoptosis [2]. Hence, an increasing demand for the 
availability of new lead compounds drives an intense search for new bioactive natural products. 
Currently, it is of particular note that pharmacologically-active compounds derived from marine 
organisms represent a promising source for developing new investigational anti-cancer drugs, as they 
produce a wide variety of metabolites that are structurally unique and biologically active [3]. 
Breast cancer remains the most commonly diagnosed type of cancer among women and a major 
health problem worldwide [1]. Despite many advances in the treatment of breast cancer, resistance to 
anti-breast cancer agents represents a major challenge to the development of successful treatment. 
Mechanistically, resistance to chemotoxic agents in breast cancer patients is most often associated with 
the action of ATP-binding cassette (ABC) drug transporters, which include ABC transporter-subfamily 
B member 1 (ABCB1, or P-glycoprotein/P-gp), subfamily C member 1 (ABCC1, or multidrug Mar. Drugs 2012, 10 
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resistance-associated protein 1/MRP1) and subfamily G member 2 (ABCG2, or breast cancer 
resistance protein/BCRP) [2,4]. 
Several new studies have shown that growth factor receptor-mediated signal transduction, such as 
the HER2/phosphoinositide-3-kinases(PI3K)/Akt signaling pathway, has been implicated in conferring 
resistance to conventional chemotherapy against breast cancer [5–8]. Moreover, the PI3K/Akt pathway 
has been implicated in the regulation of a wide variety of cellular processes including survival, 
proliferation, growth and metabolism [9]. Genetic deregulation of PI3K activity has been found in a 
wide variety of tumor types, including somatic oncogenic gain-of-function mutations and amplification 
of genes encoding key components along the pathway [10,11]. Several new studies suggest that 
HER2/PI3K/Akt signaling may confer resistance to a panel of chemotherapeutic agents with different 
mechanisms of actions: adriamycin (an anthracycline) [6–8], mitoxantrone (an anthracycline) [8],   
5-fluorourocil (an antimetabolite) [7,8], etoposide (a DNA-damaging agent) [7,8], camptothecin   
(a topoisomerase I inhibitor) [7] etc. Such resistance may be relevant to the effects of MDR in breast 
cancer. It has been documented that activation of Akt by HER2/PI-3K plays an important role in 
conferring broad-spectrum chemoresistance in breast cancer cells. Thus, Akt is believed to be a novel 
molecular target for therapies that would improve the outcome of anti-breast cancer chemotherapy in 
patients with breast cancer [12]. 
Anthracyclines are the most commonly used anti-cancer treatment. Anthracycline drugs, such as 
Epirubicin and Mitoxantrone, are still in the first-line treatment against many types of cancer, 
including acute leukemia, Hodgkin’s lymphoma and breast cancer [13,14]. Clinical application of 
anthracyclines, however, is limited by their tendency to induce multidrug resistance [14]. It is therefore 
important to identify new anthracenedione derivatives with improved pharmacological and 
toxicological profiles. In our previous study, SZ-685C [15], a secondary metabolite purified from the 
mangrove endophytic fungus No. 1403, collected from the South China Sea, was found to exhibit 
structural similarity to anthracyclines, the anti-cancer drug widely used in the clinic. We demonstrated 
that SZ-685C induces apoptosis through Akt signaling, which consequently led to antitumor effects 
both in vitro and in vivo, suggesting that SZ-685C may be a potentially promising Akt inhibitor and 
anti-cancer drug candidate [15].  
The current study attempts to address whether SZ-685C can reverse chemoresistance by suppressing 
the Akt signaling in human breast cancer cells. Our results demonstrated that SZ-685C suppressed the 
proliferation of ADR-resistant MCF-7/ADR and MCF-7/Akt breast cancer
 cells as well as the growth 
of MCF-7/ADR xenografts, suggesting a potentially promising approach to the treatment of   
ADR-resistant breast cancer. 
2. Results 
2.1. Growth Inhibition of ADR-Resistant Human Breast Cancer Cell Lines Induced by SZ-685C 
To investigate whether SZ-685C was able to inhibit the growth of ADR-resistant human breast 
cancer cells, its effects on the MCF-7/ADR, a cell line with ADR resistance derived from the parental 
MCF-7 breast cancer cells, was examined using MTS assay. Upon treatment of SZ-685C for 48 h, 
cultured MCF-7/ADR exhibited markedly inhibited growth, as compared with vehicle-controlled cells Mar. Drugs 2012, 10 
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in a dose-dependent manner (Figure 1, A–C). Calculated IC50s,  i.e., concentrations of SZ-685C 
required for decreasing the growth rate of the cells by 50%, were 4.17 μM for MCF-7/ADR (Table 1) 
and 7.38 μM for MCF-7, indicating decreasing the ADR resistance factor (RF) from 19.19 to 0.57. The 
effect of SZ-685C on the viability of ADR-resistant cell lines of other two types of human cancer, 
including K562/ADR (human erythromyeloid leukemia) and HL-60/ADR (human promyelocytic 
leukemia) were further evaluated. The results presented in Table 1 reveal significant inhibitory effects 
of SZ-685C on both tested cell lines, with IC50 values of 1.35 μM for K562/ADR and 1.76 μM for  
HL-60/ADR, and decreasing the ADR resistance factor from 58.33 to 1.24, and 54.94 to 0.91 by  
SZ-685C, respectively, after 48 h of treatment (Table 1). 
Table 1. IC50 values of SZ-685C on various ADR-resistant cancer cell lines. 
Cell Lines 
ADR SZ-685C 
IC50 RF IC50 RF 
MCF-7 0.96 - 7.38 - 
MCF-7/ADR 18.42  19.19  4.17  0.57 
MCF-7/Akt 7.69  8.01  3.36  0.46 
K562 0.15  -  1.09  - 
K562/ADR 8.75  58.33  1.35  1.24 
HL-60 0.33  - 1.94  - 
HL-60/ADR 18.13  54.94  1.76  0.91 
We also constructed a Flag-tagged constitutively active (PI3K-independent) Akt expression vector, 
termed Flag-DPH-Akt1-farn, by replacing the phospholipid-interactive PH domain of Akt1 with a 
farnesylation sequence to direct constitutive membrane anchoring, as previously described [7]. Using 
this vector, retroviral activity was generated in a modified MCF-7 cell line stably overexpressed   
Flag-DPH-Akt1-farn (MCF-7/Akt1), as well as a control pMSCV backbone vector (MCF-7/Vector). 
As shown in Figure 1B, the results of western blotting analysis of the control-vector transfected clone  
MCF-7/Vector and a representative Flag-DPH-Akt1-farn vector-transduced clone (MCF-7/Akt1) 
demonstrated that expression of high-level farnesylated Flag-DPH-Akt1-farn, but not endogenous Akt, 
a markedly increased phosphorylation of Akt1. In parallel with the observed increase of Akt 
phosphorylation, Bcl-xL, a crucial anti-apoptotic effector downstream to Akt signaling, was upregulated 
in MCF-7/Akt cells. Further analysis summarized in Table 1 suggested that the constitutively 
phosphorylated Akt conferred MCF-7 cell resistance to ADR, and, as shown in Figure 1C, SZ-685C, 
and exhibited a marked inhibition on the survival of MCF-7/Akt cells in a dose-dependent manner.  
In addition, the IC50 value was 3.36 μM for MCF-7/Akt, decreasing the ADR resistance factor from 
8.01 to 0.46. Mar. Drugs 2012, 10 
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Figure 1. Effect of SZ-685C on the growth of MCF-7/ADR and MCF-7/Akt cells. Cells 
were seeded in 96-well plates and incubated with different concentrations of SZ-685C or 
ADR as noted for 48 h at 37 °C. (A) Effect of SZ-685C on morphology of MCF-7/ADR 
(200×); (B) MCF-7/Akt cells stably expressing Akt were assessed for changes in 
phosphorylation status of Akt at Thr308 and Ser473 and total levels of Flag-Akt protein; 
(C) Viabilities were determined by MTS assay. Data points are presented as means ± SD of 
triplicated experiments. The Student’s t test was performed to compare the growth of 
MCF-7/ADR and MCF-7/Akt cells (* indicates p < 0.05, and ** indicates p < 0.01). 
 
2.2. SZ-685C Induced Apoptosis in MCF-7/ADR and MCF-7/Akt Cells 
Apoptosis assays exhibited that upon treatment of SZ-685C for 12 h at 2, 4, 8 μM, respectively, 
numbers of apoptotic MCF-7/ADR and MCF-7/Akt cells (Annexin V
+/PI
−), as revealed by   
Annexin-V binding, markedly increased in a dose-dependent manner (Figure 2A). When the Terminal 
deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay was performed to 
assess DNA fragmentation, as a late event in the process of apoptosis of MCF-7/ADR cells, a higher 
amount of TUNEL-positive cells were visualized in MCF-7/ADR cells treated for 24 h with SZ-685C 
at 8 μM, as compared to the control (Figure 2B). The results of two apoptosis assays, i.e., the Annexin 
V-binding and TUNEL assays, strongly suggested a pro-apoptotic effect of SZ-685C on ADR-resistant 
MCF-7 cells. Mar. Drugs 2012, 10 
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Figure 2. Induction of apoptosis in MCF-7/ADR and MCF-7/Akt cells by SZ-685C.   
(A) AnnexinV-FITC/PI staining of MCF-7/ADR and MCF-7/Akt cells treated with   
SZ-685C. Cells were exposed to different concentrations (0, 2, 4, 8 μM) of SZ-685C and 1 
μM ADR for 12 h. Cells were collected and subjected to Annexin V-FITC/PI staining and 
analyzed by flow cytometry. (B) TUNEL assay of MCF-7/ADR cells treated with   
SZ-685C. Cells were treated with 8 μM SZ-685C as noted for 24 h and labeled with 
fluorescein-12-dUTP (red) and PI counterstaining (green). 
 Mar. Drugs 2012, 10 
 
 
700
2.3. Activation of Both the Extrinsic and Intrinsic Apoptotic Pathways by SZ-685C 
Recent evidence suggests that apoptotic mechanisms mediate drug-induced cell death, and that the 
activation of effector caspases plays a central role in the execution of apoptosis [16]. Therefore, to 
estimate the cytocidal potential of chemotherapeutic agents, it is important to quantify their abilities to 
induce apoptosis and activate caspases. To further characterize the cell apoptotic process in   
MCF-7/ADR and MCF-7/Akt cells, pro-apoptotic caspases, i.e., caspase-9 and -8, and the effector 
molecule PARP, were examined on the two cell lines treated or untreated, comparatively, with   
SZ-685C. Our results (Figure 3A) displayed that treatments with various concentrations of SZ-685C 
for 24 h dramatically increased activating cleavage of caspase-8 dose-dependently in MCF-7/ADR and 
MCF-7/Akt cells. In consistence with the results of western blotting analysis, the enzymatic activity of 
caspase-8 in an enzymatic assay showed a dose-dependent increase with SZ-685C treatment (Figure 3B). 
Concurrently, cleavage of the caspase-9 precursor and increased caspase-9 activity were also detected 
(Figure 3A,B). Cleavage of PARP from 116 kDa to 85kDa was clearly demonstrated after SZ-685C 
treatment both in MCF-7/ADR and MCF-7/Akt cells (Figure 3A). Taken together, these data suggest 
that apoptosis induced by SZ-685C in ADR-resistant breast cancer cells may involve both intrinsic and 
extrinsic pathways. 
Figure 3. Activation of caspases and PARP in MCF-7/ADR and MCF-7/Akt cells by   
SZ-685C. (A) Western blotting analysis of caspases and PARP in MCF-7/ADR and   
MCF-7/Akt cells after SZ-685C treatment at different concentrations for 48 h using 
antibodies against caspase-8, -9, and PARP. Actin was used as an internal control;   
(B) Enzymatic activities of caspases in SZ-685C treated MCF-7/ADR and MCF-7/Akt 
cells, as assessed by colorimetric assay. The fold-increases in the activities of caspases-8 
and -9 were determined by comparison with those of the treated control cells. Results are 
presented as means ± SD. The asterisks indicate statistically significant differences as 
compared with the control: * p < 0.05, ** p < 0.01. 
 Mar. Drugs 2012, 10 
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Figure 3. Cont. 
 
2.4. Inhibition of Akt Phosphorylation and Its Downstream Substrates by SZ-685C 
In an effort to further understand the signaling cascade that mediates the pro-apoptotic effect of  
SZ-685C on MCF-7/ADR and MCF-7/Akt cells, changes in phosphorylation status of Akt were 
investigated. As shown in Figure 4, for both tested ADR-resistant breast cancer cell lines, in which Akt 
was constitutively activated upon treatment with ADR (Figure 4A), SZ-685C treatment resulted in a 
dose-dependent decrease of phospho-Ser473-Akt and phospho-Thr308-Akt without an effect on total 
Akt expression (Figure 4B). Bad is a pro-apoptotic member of the Bcl-2 family that promotes cell 
death by displacing Bax from binding to Bcl-2 and Bcl-xL. Phosphorylation at Ser112 and Ser136 
promotes binding of Bad to 14-3-3 proteins to prevent an association between Bad with Bcl-2 and  
Bcl-xL. Akt can phosphorylate Bad at Ser136 to promote cell survival [17]. In parallel with the 
observed reduction of Akt phosphorylation, phosphorylation of Bad (Ser136), a crucial mediator 
downstream of Akt signaling, was also inhibited by SZ-685C treatment in a dose-dependent manner 
without an effect on total Bad expression (Figure 4B). Moreover, Bcl-xL, another anti-apoptotic 
effector downstream to Akt signaling, was downregulated in response to SZ-685C treatment in   
MCF-7/ADR and MCF-7/Akt cells (Figure 4B). Mar. Drugs 2012, 10 
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Figure 4. Effect of SZ-685C on the Akt signaling pathway in MCF-7/ADR and MCF-7/Akt 
cells. Cells were treated with different concentrations of ADR (A) and SZ-685C (B) for  
48 h as noted. Western blotting analysis was performed using antibodies against   
phospho-Akt (Ser473 or Thr308), total Akt, phospho-Bad (Ser 136), total Bad, and Bcl-xL, 
with Actin used as a loading control. 
 
2.5. Anti-Tumor Effect of SZ-685C on ADR-Resistant Breast Cancer Xenografts in Vivo 
To determine the anticancer activity of the SZ-685C against ADR-resistant breast cancer in vivo, we 
next tested the therapeutic effect of SZ-685C on MCF-7/ADR xenograft in a nude mice model. When 
the tumor volumes were assessed on day 6 after inoculation, all the animals in the group had developed 
spinal cord tumors (7/7, or 100%), with a mean volume (±SD) of approximately 30 mm
3. The growth Mar. Drugs 2012, 10 
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of the xenograft tumors were monitored following injection with SZ-685C or ADR. A marked 
inhibition of the growth of the xenografted tumors formed by the MCF-7/ADR cells treated with  
SZ-685C was observed. After six SZ-685C injections, the volume of the xenografted breast tumor was 
significantly inhibited by 63.23% in SZ-685C-treated nude mice, as compared with the   
tumor-inhibitory rate, i.e., 29.11% of ADR (Figure 5A). The weight of the xenografted tumor at 
experimental endpoint was significantly inhibited by 64.32% and 28.34%, respectively, in SZ-685C- 
and ADR-treated nude mice (Figure 5B). Furthermore, decreases of phospho-Ser473-Akt,   
phospho-Thr308-Akt and Bcl-xL, without an effect on total Akt expression, were observed in two 
representative tumor tissues, followed by treated with SZ-685C (Figure 5C). Meanwhile, no detectable 
toxic effects, such as signs of discomfort, change in animal behavior, or weight loss (Figure 5D), was 
found in SZ-685C-treated animals. In contrast, the ADR-treated animals exhibited a certain degree of drug 
toxicity, including significant weight loss (Figure 5D). These data strongly suggest that systemically-
delivered SZ-685C was able to inhibit the growth of established ADR-resistant tumors in vivo. 
Figure 5. In vivo anti-tumor effect of SZ-685C on xenografted MCF-7/ADR tumors in 
nude mice. Viable MCF-7/ADR cells (1 × 10
7 cells/mouse) were inoculated subcutaneously 
in the right mammary pads of female nude mice. After solid tumor formation, the mice 
received an intraperitoneal injection of SZ-685C (50 mg/kg), ADR (8 mg/kg) or   
vehicle-control (0.5% DMSO) every four days for about one month. (A) Time-response 
curve of the effect of SZ-685C on the growth of xenografted MCF-7/ADR tumor;   
(B) Inhibition ratio calculated, based on tumor tissues weight for each group; (C) Western 
blotting analysis was performed using antibodies against phospho-Akt (Ser473 or Thr308), 
total Akt, and Bcl-xL, with Actin used as a loading control, in two representative tumor 
tissues, followed by treated with SZ-685C; (D) Time-response curve of the effect of SZ-685C 
or ADR on the body weight of the xenografted mice. Results are presented as means ± SD. 
The asterisks indicate statistically significant differences as compared with the control, 
with * and ** indicating p < 0.05 and p < 0.01, respectively, as tested using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparisons. 
 Mar. Drugs 2012, 10 
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Figure 5. Cont. 
 
3. Discussion 
Anthracyclines, such as ADR, are a class of anti-cancer chemotherapeutic drugs commonly used in 
the clinic to treat various types of human cancer, including breast cancer. Clinical application of 
anthracyclines, however, is frequently impeded by their severe adverse side effects, e.g.,   
cardiotoxicity [18,19], and myelosuppression [20], as well as the tendency to induce multidrug 
resistance [21]. There is, therefore, an urgent need to identify new anthracenedione derivatives with 
improved pharmacological and toxicological profiles. In our previous study that aimed at screening 
novel anticancer lead compounds from a metabolite library derived from marine microorganisms 
isolated from the South China Sea, SZ-685C was selected for its potent anticancer activity in vitro as 
well as in vivo [15]. We have demonstrated that SZ-685C selectively kills cancer cells via activating 
both caspase-8- and caspase-9-mediated apoptotic mechanisms by, at least in part, suppressing the 
phosphorylation of Akt. In our current study, we provide evidence that SZ-685C is able to kill breast 
cancer cells resistant to the anti-cancer effect of ADR, and thereby might represent a new, potentially 
promising approach to the treatment of anthrocycline-resistant breast cancer. 
This study employed a cellular model MCF-7/ADR that was originally derived from the human 
breast cancer cell line MCF-7, and selected for resistance to ADR. It is of note that the parental cell 
line of the MCF-7/ADR and MCF-7/Akt models, i.e., the MCF-7 cell line, is relatively well 
differentiated and estrogen-dependent, containing receptors for estrogen and progesterone [22,23]. 
Interestingly, these estrogen responses are lost in MCF-7/ADR cells. It has been reported that the 
MCF-7/ADR cells form tumors in the nude mice in the absence of exogenous estrogen administration, 
while the formation of tumors in nude mice by wild-type MCF-7 cells is estrogen-dependent [24]. 
Furthermore, MDR presented by MCF-7/ADR cells is also associated with a loss of mitogenic 
response to estrogen and the development of cross-resistance to the anti-estrogen, 4-hydroxytamoxifen. 
These changes in the hormonal sensitivity and estrogen-independent tumorigenicity of the   
multidrug-resistant MCF-7/ADR cell line might be attributable to loss of estrogen receptor and a 
concomitant increase in the level of other receptors, such as those for epidermal growth factor. The Mar. Drugs 2012, 10 
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results obtained from our current study warrants further exploration of the possibility of SZ-685C to 
sensitize breast cancer cells to anti-estrogen drugs. 
A second test model used in our study, i.e., the MCF-7/Akt cell, is a derivative of the MCF-7 cells, 
engineered to express constitutively activated Akt. As a central mediator of PI3K signaling, Akt plays 
a key role in protecting cells from various apoptotic stimuli by phosphorylating diverse downstream 
targets, such as Forkhead family transcription factors, Bad, Bcl-xL, InB kinase, MDM2 and 
procaspase-9 [9,25]. Akt also interacts, directly or indirectly, with numerous other regulatory proteins, 
including cyclin D, p21
Cip1, glycogen synthase kinase (GSK)-3, and mTOR [9,25]. The PI3K/Akt 
pathway has thus been implicated in the regulation of a wide variety of cellular processes, including 
survival, proliferation, growth, and metabolism. Under physiological conditions, PI3Ks were localized 
to the plasma membrane upon activation, where it phosphorylates the substrate phosphatidylinositol-4, 
5-diphosphate (PIP2), integral components of the plasma membrane, to phosphatidylinositol-3, 4,   
5-triphosphate (PIP3) [26]. PIP3 functions as a membrane-bound second messenger by recruiting a 
subset of pleckstrin homology (PH), domain-containing proteins, such as Akt and 3-phosphoinositide-
dependent kinase 1 (PDK1), to the membrane, in which they become activated and initiate downstream 
signaling events [26]. 
It was previously reported that MCF-7 cells expressing a constitutively active Akt, in which the 
phospholipid-interactive PH domain of Akt was replaced by a farnesylation sequence for constitutive 
membrane anchorage, showed a broad-spectrum chemoresistance on breast cancer cells [6,7]. Here, we 
also generated MCF-7/Akt stable cell lines by using the same approach, in which Akt protein was 
cleavable by the farnesyl-esterases that were expressed in mammalian cells, thereby allowing its 
cytoplasmic relocalization. Our results obtained from the current study indicate that the Akt kinase in 
MCF-7/Akt was constitutively active, as expected, and was sufficient to mediate resistance to ADR. 
The results are in line with the observation that the modified MCF-7 cells expressing constitutively 
activated Akt or a high level of HER2 were resistant to a panel of chemotherapeutic agents [6–8]. 
These results strongly support the hypothesis that deregulated over-activation of Akt plays an 
important role in resistance to chemotherapy. SZ-685C, a novel anthracycline compound, as evidenced 
in this study, is able to potently suppress the phosphorylation of Akt and subsequently induce apoptosis 
in ADR-resistant breast cancer cells in which Akt kinase is over-activated. The involvement of Akt in 
human cancer oncogenesis and chemoresistance indicates that Akt is an important target   
for screening anti-cancer drugs against various types of cancer cells including those resistant to   
conventional chemotherapy. 
4. Experimental Section  
4.1. Chemicals 
Unless otherwise stated, laboratory chemicals, bacterial culture reagents, antibiotics and disposable 
labware were purchased from the Sangon Biotech (Shanghai, China), Sigma-Aldrich (St. Louis, MO, 
USA), or BBI (Gaithersburg, MD, USA). SZ-685C was prepared and purified from mangrove 
endophytic fungus No. 1403 as previously reported [15], and its structure was identified by 
interpretation of spectral data (MS, 
1H NMR, 
13C NMR, 2D NMR) and X-ray single crystal diffractive Mar. Drugs 2012, 10 
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technique. The compound was dissolved in 0.5% dimethylsulfoxide (DMSO) at a concentration of  
1 mM as stock solution, and diluted according to experimental requirements when used. ADR was 
purchased from Merck (Merck KGaA, Darmstadt, Germany). 
4.2. Cell Culture 
MCF-7/ADR (Human breast cancer), K562/ADR (Human erythromyeloid leukemia), and   
HL-60/ADR cells (Human promyelocytic leukemia) were obtained from Keygen Biotech (China). 
Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco-Invitrogen, Carlsbad, CA, 
USA), supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), 2 mM L-glutamine,  
100 μg/mL streptomycin and 100 Units/mL penicillin (Gibco-Invitrogen, Carlsbad, CA), 1 μM ADR 
(to maintain ADR resistance phenotype, upon treatment with or without SZ-685C). All of the cells 
used in this study were maintained at 37 °C in a humidified atmosphere, 5% CO2 incubator. 
4.3. Establishment of Stable Cell Lines Expressing Constitutively Activated Akt 
Flag-tagged constitutively activated (PI3K-independent) Akt expression vector was constructed by 
replacing the phospholipid-interactive PH domain of Akt1 with a farnesylation sequence for directing 
constitutive membrane anchoring, termed Flag-DPH-Akt1-farn vector, as previously described [7]. 
The final PCR product encoded Akt1 that lacks the PH domain (aminoacids 1–106) with an N-terminal 
fusion of the Flag epitope (DYKDDDDK) and a C-terminal fusion of a poly-basic tail and a 
farnesylation sequence (KKKKKKSKTKCVIM). The PCR fragment was subcloned into the   
pMSCV-Puro vector (Invitrogen, Carlsbad, CA, USA) in the restriction sites Bgl II and EcoR I. The 
final Akt sequence was verified by nucleotide sequencing analysis. Recombinant retroviruses were 
prepared by transfecting 2 μg of each of the pMSCV-Flag-DPH-Akt1-farn plasmid DNAs and 
pMSCV-Puro vector into the packaging cells 293FT, together with 2 μg of the pIK plasmid. These 
viruses were used to infect MCF-7 cells, and stably transduced cell lines were selected in DMEM 
medium supplemented with puromycin (5 μg/mL). To verify the expression of the Flag-DPH-Akt1-farn 
proteins, cell lysates were collected and examined using Western blotting analysis. 
4.4. Cell Viability Analysis 
Cells (1 × 10
4 cells/well) in growth medium were seeded in 96-well flat-bottom plates (in triplicates) 
for 24 h in the absence or presence of various concentrations of SZ-685C and 1 μM ADR for 
additional 48 h. Cell viability was measured by using the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay to monitor cell proliferation, 
according to the manufacturer’s recommendations. Briefly, 20 μL MTS solution (CellTiter 96Aqueous 
One Solution reagent, Promega, Madison, WI, USA) were added to each well and incubated for an 
additional 4 h at 37 °C. The absorbance was measured at 490 nm using a microplate reader (Bio-Tek 
Synergy 2, Winooski, VT, USA). The control group was defined as cells that were treated with 1 μM 
ADR and not exposed to SZ-685C. Cell growth inhibition was determined using the following formula 
according to a previously published method: growth inhibition (%) = (1 − O.D. of treated cells/O.D. of 
control cells) × 100% [15]. The half maximal inhibitory concentration (IC50) was calculated with Mar. Drugs 2012, 10 
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Bliss’s software and the data were analyzed by SPSS [15]. The resistance factor (RF) was calculated as 
the ratio of the IC50 for the resistant cell line to the IC50 for the sensitive cell line. All experiments were 
performed three times from which mean values were calculated. 
4.5. Annexin V-FITC/Propidium Iodide (PI) Staining Assay 
The Annexin V/Propidium iodide (PI) dual staining assay was employed to detect viable and early 
apoptotic cells. Cells (2 × 10
5 cells/well) were seeded in 60 mm plates and allowed to settle for 24 h 
before treatment with various concentrations (0, 2, 4, 8 μM) of SZ-685C and 1 μM ADR for an 
additional 12 h. The cells were trypsinized after washing for three times with PBS, and incubated in 
500 μL binding buffer containing annexin V-FITC and PI in the dark for 10 min at room temperature, 
according to the manufacturer’s instructions (Keygen Biotech, China), followed by measurement with 
flow cytometric (FCM) analysis (FCAScan; Becton-Dickinson Immunocytochemistry Systems, San Jose, 
CA, USA). The percentage of apoptotic cells was defined by their distribution in a fluorescence dot 
plot using WinMdi 2.8 software [27]. 
4.6. Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick End Labeling (TUNEL) Assay 
Apoptotic DNA fragmentation induced by SZ-685C was examined using the in situ DeadEnd
TM 
Fluorometric TUNEL System assay kit (Promega, Madison, WI, USA) according to the manufacturer’s 
protocol. Briefly, cells were plated in 24-well flat-bottom plates at a density of 1 × 10
5 cells/well and 
treated with 8 μM SZ-685C and 1 μM ADR, or 1 μM ADR alone (Control group) for 24 h. Following 
SZ-685C treatment, cells were fixed in 4% paraformaldehyde at 4 °C for 30 min. Fixed cells were then 
permeabilized in 0.1% Triton X-100, and labeled with fluorescein-12-dUTP using terminal 
deoxynucleotidyl-transferase. After rinsing with PBS twice, the nuclei of cells were double-stained 
with PI (1 μg/mL) for 15 min. The localized green fluorescene of apoptotic cells (fluorescein-12-dUTP) 
was detected by fluorescence microscopy (Zeiss Axiovert100M, Carl Zeiss, Germany). 
4.7. Caspase Activity Assay 
Activity of Caspase-8 and Caspase-9 was measured using a caspase colorimetric assay kit (Keygen 
Biotech, China), according the manufacturer’s protocol. Briefly, following treatment of   
SZ-685C at different concentrations and 1 μM ADR for 48 h, cells were harvested and washed with 
PBS for two times, then resuspended in chilled 1 × lysis buffer. Cells lysates were centrifuged for  
1 min at 10,000 × g after incubation on ice for 60 min. The supernatant was collected in a fresh tube, 
and the total protein concentration was determined by the Bradford protein assay kit (Keygen Biotech, 
China), according to the manufacturer’s protocol. Subsequently, 150 μg of each sample was diluted 
with 50 μL lysis buffer and added to 50 μL of 2 × reaction buffer containing 10 mM DTT in a 96-well 
plate. Then, 5 μL of a colorigenic substrate, IETD-pNA or LEHD-pNA, was added to each well, and 
the plate was incubated at 37 °C in the dark for 4 h. Absorbance at 405 nm was determined using a 
microplate reader (Bio-Tek Synergy 2, Winooski, VT). Mar. Drugs 2012, 10 
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4.8. Western Blotting Analysis 
After treatment with SZ-685C or ADR at different concentrations for 48 h, floating cells and adherent 
cells were collected and lysed in 1× sample buffer containing 50 mM Tris-HCl (pH 7.4), 1 mM PMSF, 
10% glycerol, 6% SDS, 5% mercaptoethanol and 0.1% bromophenol blue before sonication. The 
protein concentration of the extracts was determined by the Bicinchoninic Acid Protein Assay Kit 
(Thermo Fisher Scientific, Rockford, IL), according to the manufacturer’s instructions with BSA as the 
standard. The total cell lysate (40 μg of protein) was subjected to SDS-PAGE, and then transferred to 
PVDF membranes. After blocking with blocking buffer (Tris-buffered saline, TBS, containing 5% 
non-fat milk) for 1 h at room temperature, the membranes were incubated overnight at 4 °C with specific 
primary antibodies, namely: mouse anti-human caspase-8, mouse anti-human caspase-9 (BD Biosciences, 
San Jose, CA, USA); rabbit anti-human PARP, rabbit anti-human phospho-Akt (Ser473), rabbit   
anti-human phospho-Akt (Thr 308), rabbit anti-human Akt, Phospho-Bad (Ser136) antibody, Bad 
antibody, Bcl-xL Antibody (Cell Signaling, Beverly, MA, USA), and monoclonal anti-Actin antibody 
(Sigma-Aldrich, St. Louis, MO, USA). Further incubation with appropriate horseradish peroxidase 
(HRP)-conjugated secondary antibodies, depending on the primary antibody used, was performed for  
1 h at room temperature. Immuno-reactive bands were detected using enhanced chemiluminescence kit 
(Thermo Fisher Scientific, Rockford, IL, USA) with Kodak film. Actin was used as a loading control 
for quantity normalization. 
4.9. Xenografted Tumor Model and Anti-Tumor Effect of SZ-685C in Vivo 
Female BALB/c-nu mice (18–20 g) were purchased from the Shanghai Laboratory Animal Center, 
Chinese Academy Sciences (Shanghai SLAC Laboratory Animal Co. LTD.), and were housed in 
barrier facilities on a 12 h light/dark cycle. Three days before implanting MCF-7/ADR cells, mice 
received a 0.8 mg β-estradiol pellet (Innovative Research, Toledo, OH, USA) subcutaneously in their 
front-back area. On day zero, MCF-7/ADR cells (1 × 10
7 cells in 0.1 mL/mouse) were inoculated 
subcutaneously in the right mammary pad. Mice were ear-tagged and randomly divided into two 
treatment groups and a control group in a blinded fashion before treatment. On day six, formed tumors 
were measured, and the two treatment groups of animals received an intraperitoneal (i.p.) dosage of  
200 μL SZ-685C (50 mg/kg body weight) and ADR (8 mg/kg body weight), respectively, every four 
days, while the vehicle-control animals received daily i.p. doses of 200 μL 0.5% DMSO solution per 
mouse. Tumors were measured every three days in a blinded manner by measuring perpendicular 
diameters with a digital caliper, and tumor volumes (mm
3) were calculated using the following formula: 
volume = width × width × length × π/6. Data were presented as the means ± standard deviation (SD) of 
seven mice in each group. At the endpoint of the experiment, all the animals were euthanized, and the 
tumors were dissected and weighed. All experimental procedures were approved by the Institutional 
Animal Care and Use Committee of Sun Yat-sen University. 
4.10. Statistical Analysis 
The data given in the text are expressed as means ± SD. For MTS assay, statistical analyses were 
undertaken using the Student’s t test. Statistical significances of the differences in tumor volumes Mar. Drugs 2012, 10 
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between treatment and control groups were determined by one-way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparisons. 
5. Conclusions  
In conclusion, our study provides the evidence that SZ-685C is a potent apoptosis inducer in breast 
cancer cells resistant to conventional ADR treatments in vitro as well as in vivo, and that such effects 
may be through suppressing Akt signaling, supporting the potential usefulness of combining SZ-685C 
with other therapeutic drugs in combating MDR in breast cancer chemotherapy. 
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